Highlights include:
> Respect-LM dosing shows continued feasibility and safety of up to 44 mCi of intrathecal Rhenium (186Re) Obisbemeda
> High absorbed radiation doses, mean circulating tumor cell reductions, and median overall survival of 12 months continue to show clinical promise
More details including additional key ReSPECT-LM highlights through Cohort 4: https://bit.ly/3yErnKr
Recent Comments